ASH 2010 Homepage Header

News
Article

Oncology NEWS International reports on critical information from the American Society of Hematology's 52nd annual meeting.

 

  • Rituximab instead of ‘watch and wait’ policy in asymptomatic follicular lymphoma causes controversy

  • Ofatumumab generates high response rates in refractory CLL

  • Industry update: Early-stage trials establish pathways for new treatment agents
     
  • More Coverage from ASH 2010

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
4 experts in this video
2 experts in this video
Related Content